SCHEMBL4430966

SCHEMBL4430966

Cc1cc(F)c(NC(=O)Nc2cc(C(C)(C)C)nn2C)cc1-c1cc2cnc(N)nc2n(C)c1=O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRAF P15056 7/20 0.56
RAF1 P04049 4/20 0.56
KDR P35968 3/20 0.47
LMNA P02545 2/20 0.43
MAPK14 Q16539 8/20 0.43
MAPK13 O15264 3/20 0.42
KRAS P01116 2/20 0.42
MAP2K2 P36507 2/20 0.42
MAP2K1 Q02750 2/20 0.42
ABL1 P00519 1/20 0.41
MAPT P10636 1/20 0.41
MAPK12 P53778 1/20 0.40
MAPK11 Q15759 1/20 0.40
FGFR1 P11362 2/20 0.39
FGFR2 P21802 2/20 0.39
FGFR4 P22455 2/20 0.39
FGFR3 P22607 2/20 0.39
EGFR P00533 1/20 0.39
SRC P12931 1/20 0.39
ARAF P10398 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5066964 0.89 BRAF (0.70) BRAFRAF1KDRLMNAMAPK14
SCHEMBL1521762 0.87 BRAF (0.43) BRAFRAF1KDRLMNAMAPK14
SCHEMBL5065431 0.87 BRAF (0.46) BRAFRAF1KDRLMNAMAPK14
SCHEMBL5062602 0.86 BRAF (0.55) BRAFRAF1KDRMAPK14MAPK13
SCHEMBL5061954 0.85 BRAF (0.60) BRAFRAF1KDRLMNAMAPK14
SCHEMBL4563448 0.83 BRAF (0.49) BRAFRAF1KDRMAPK14MAPK13
SCHEMBL4277871 0.83 BRAF (0.58) BRAFRAF1KDRLMNAMAPK14
SCHEMBL4419489 0.81 BRAF (0.58) BRAFRAF1LMNAMAPK14MAPK13
SCHEMBL5062738 0.80 BRAF (0.58) BRAFRAF1KDRLMNAMAPK14
SCHEMBL5061828 0.80 BRAF (0.60) BRAFRAF1KDRLMNAMAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120289540-A1 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES DECIPHERA PHARMACEUTICALS, LLC (US) 2012-11-15 US disclosed
US-8188113-B2 For example, 1-(5-(2-amino-8-methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-6-yl)-2-fluorophenyl)-3-(3-tert-butyl-1-phenyl-1H-pyrazol-5-yl)urea; for treatment of mammalian cancers and inflammatory diseases including rheumatoid arthritis, retinopathies DECIPHERA PHARMACEUTICALS, INC. (US) 2012-05-29 US disclosed
EP-2063897-A2 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES Deciphera Pharmaceuticals, LLC. (US) 2009-06-03 EP disclosed
US-20080114006-A1 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PARMACEUTICALS, LLC (US) 2008-05-15 US disclosed
WO-2008034008-A2 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES DECIPHERA PHARMACEUTICALS, LLC. (US) 2008-03-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120289540-A1 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES BRAF, PRKDC, RAF1 BRAF 1/4885RAF1 3/4885KDR 500/4885
US-20080114006-A1 Kinase inhibitors useful for the treatment of proliferative diseases BRAF, PRKDC, RAF1 BRAF 1/4885RAF1 3/4885KDR 500/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.